Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients (NCT06892093) | Clinical Trial Compass
RecruitingNot Applicable
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
China308 participantsStarted 2025-08-07
Plain-language summary
This study aims to evaluate the efficacy and safety of probiotics for the prevention of diarrhea in patients with breast cancer receiving the tyrosine kinase inhibitor (TKI) Neratinib.
Study Design: This is a prospective, randomized controlled clinical trial. Participants will be randomly assigned to either a probiotics intervention group or a placebo-controlled group. Both groups will receive prophylactic loperamide according to the FDA-recommended dosing schedule for neratinib-associated diarrhea.
Primary Objective: To evaluate the efficacy of probiotics in reducing the incidence and severity of diarrhea in patients receiving Neratinib.
Secondary Objectives: This study will also investigate the effects of probiotics on gut microbiota composition and their potential impact on drug efficacy.
Study Duration: Enrollment is planned from August 2025 to June 2027 at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Both the intervention and control groups will receive treatment for a total of six weeks (two cycles of three weeks each). No post-treatment observation period is included.
Eligibility Criteria: Participants must be diagnosed with HER2-positive breast cancer and scheduled to receive Neratinib. Exclusion criteria include patients with severe gastrointestinal disorders or recent probiotic consumption.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Female patients aged ≥18 years, diagnosed with HER2-positive breast cancer.
✓. Scheduled to receive Neratinib therapy (monotherapy or in combination), based on clinical guidelines.
✓. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with an expected survival of at least 3 months.
✓. Left ventricular ejection fraction (LVEF) ≥ 50%.
✓. Resolution of any prior treatment-related toxicity to Grade ≤1 (per CTCAE v5.0), with AST and ALT ≤ 2.5 × the upper limit of normal (ULN), and total bilirubin ≤ 1.5 × ULN.
✓. Adequate bone marrow function, defined as:
✓. No persistent gastrointestinal symptoms, such as hematochezia, chronic constipation, or abdominal pain.
✓. No evidence of structural gastrointestinal abnormalities confirmed by gastroscopy or other relevant examinations.
Exclusion criteria
✕. Conditions that significantly impair swallowing, digestion, or gastrointestinal drug absorption.
What they're measuring
1
Incidence of Grade ≥3 Diarrhea
Timeframe: Up to 6 weeks
Trial details
NCT IDNCT06892093
SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
✕. History of chronic gastrointestinal diseases, including but not limited to inflammatory bowel disease (IBD), gastrointestinal tumors, or malabsorption syndromes.
✕. Severe cardiovascular diseases that may interfere with study treatment, including but not limited to:
✕. Known hypersensitivity to any component of Neratinib, probiotics, placebo, or loperamide.
✕. Prior participation in any clinical trial involving investigational drugs within 4 weeks prior to enrollment, or chronic use of medications that may induce constipation within 6 months.
✕. Pregnant or lactating women, or those unwilling to use effective contraception during the study period.
✕. Any medical, psychiatric, or social condition that, in the investigator's judgment, could compromise the safety of the participant, interfere with study participation, or confound the study results.